113 related articles for article (PubMed ID: 34425735)
1. Myelosuppression in patients treated with
Blakkisrud J; Løndalen A; Dahle J; Martinsen AC; Kolstad A; Stokke C
Acta Oncol; 2021 Nov; 60(11):1481-1488. PubMed ID: 34425735
[TBL] [Abstract][Full Text] [Related]
2. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Blakkisrud J; Løndalen A; Dahle J; Turner S; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):55-61. PubMed ID: 27587710
[TBL] [Abstract][Full Text] [Related]
3. Pre-dosing with lilotomab prior to therapy with
Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
Blakkisrud J; Holtedahl JE; Løndalen A; Dahle J; Bach-Gansmo T; Holte H; Nygaard S; Kolstad A; Stokke C
J Nucl Med; 2018 Apr; 59(4):704-710. PubMed ID: 28848035
[No Abstract] [Full Text] [Related]
5. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
Blakkisrud J; Løndalen A; Martinsen AC; Dahle J; Holtedahl JE; Bach-Gansmo T; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):48-54. PubMed ID: 27493270
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT and Dosimetric Studies of
Løndalen A; Blakkisrud J; Revheim ME; Dahle J; Kolstad A; Stokke C
Mol Imaging Biol; 2022 Oct; 24(5):807-817. PubMed ID: 35486292
[TBL] [Abstract][Full Text] [Related]
7.
Malenge MM; Patzke S; Ree AH; Stokke T; Ceuppens P; Middleton B; Dahle J; Repetto-Llamazares AHV
J Nucl Med; 2020 Oct; 61(10):1468-1475. PubMed ID: 32245896
[TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of
Løndalen A; Blakkisrud J; Revheim ME; Madsbu UE; Dahle J; Kolstad A; Stokke C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1902-1914. PubMed ID: 33196921
[TBL] [Abstract][Full Text] [Related]
9. Combination of
Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Kolstad A; Illidge T; Bolstad N; Spetalen S; Madsbu U; Stokke C; Blakkisrud J; Løndalen A; O'Rourke N; Beasley M; Jurczak W; Fagerli UM; Kaščák M; Bayne M; Obr A; Dahle J; Rojkjaer L; Pascal V; Holte H
Blood Adv; 2020 Sep; 4(17):4091-4101. PubMed ID: 32877524
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
12. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
14. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
15. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
Larsson E; Ljungberg M; Martensson L; Nilsson R; Tennvall J; Strand SE; Jonsson BA
Med Phys; 2012 Jul; 39(7):4434-43. PubMed ID: 22830776
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic effectiveness of
Pichard A; Marcatili S; Karam J; Constanzo J; Ladjohounlou R; Courteau A; Jarlier M; Bonnefoy N; Patzke S; Stenberg V; Coopman P; Cartron G; Navarro-Teulon I; Repetto-Llamazares A; Heyerdahl H; Dahle J; Bardiès M; Pouget JP
Leukemia; 2020 May; 34(5):1315-1328. PubMed ID: 31836849
[TBL] [Abstract][Full Text] [Related]
17. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During
Hagmarker L; Svensson J; Rydén T; van Essen M; Sundlöv A; Gleisner KS; Gjertsson P; Bernhardt P
J Nucl Med; 2019 Oct; 60(10):1406-1413. PubMed ID: 30902877
[TBL] [Abstract][Full Text] [Related]
18. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
19. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
Wiseman GA; Leigh B; Erwin WD; Lamonica D; Kornmehl E; Spies SM; Silverman DH; Witzig TE; Sparks RB; White CA
Cancer; 2002 Feb; 94(4 Suppl):1349-57. PubMed ID: 11877765
[TBL] [Abstract][Full Text] [Related]
20. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
